HIGH-DOSE THERAPY INCLUDING CARBOPLATIN ADJUSTED FOR RENAL-FUNCTION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM-CELL TUMOR - OUTCOME AND PROGNOSTIC FACTORS

Thirty-one consecutive patients with relapsed or refractory GCT receiv ed an HDT schedule including carboplatin, the dose of which was adjust ed to measured glomerular filtration rate. There was one HDT-associate d death (3%), due to acute renal failure. The 3-year probability of ov erall and disease-free survival for 21 patients with primary refractor y disease or responsive relapse was 60% and 42%, respectively while no ne of ten patients with refractory relapse have survived disease free.